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Pleural mesothelioma is a heterogeneous malignancy, both in its natural history and in the varied approaches to its 
management across the globe. Practice patterns vary signifi-
cantly not only among, but also within countries. Fundamental 
questions such as, which patient (if any) will benefit from sur-
gery, and the relative merits of an extrapleural pneumonectomy 
(EPP) versus a radical pleurectomy/decortication (P/D), are 
argued quite vociferously by their respective proponents.1–3 
Unfortunately, far too many strongly held opinions about 
the management of this uncommon cancer have been based 
on selected small data sets from single-center, retrospective 
series.3,4 And until quite recently, there have been few multi-
institutional or international randomized trials to evaluate sys-
temic or surgical treatments in mesothelioma patients.5–9
To optimally determine the effectiveness of a given 
intervention, a uniform population of patients should be 
readily definable; this is a cardinal role of cancer staging. 
Unfortunately, a widely applicable and reliable staging system, 
useful in both surgical and nonsurgical candidates, has long 
been an elusive goal for mesothelioma researchers. Several 
staging systems have been proposed over the past few decades. 
Not surprisingly, most were derived from small, single-institu-
tion data sets that were not externally validated. The Butchart 
system, for example, was developed from a data set of only 
29 patients.10 Staging systems devised by Mattson, Chahinian, 
Boutin, Sugarbaker, and others, had similar limitations.4,11–13
The International Mesothelioma Interest Group/
International Association for the Study of Lung Cancer stag-
ing system, proposed by Valerie Rusch in 199514 and adopted 
by the UICC (International Union Against Cancer)15 and the 
American Joint Commission on Cancer16 as a worldwide 
standard, was a consensus document, developed by experts in 
the disease who analyzed several small retrospective surgical 
databases. This tumor, node, metastasis system was a signifi-
cant step forward, but it was still based on a limited number 
of subjects. It has also been challenging to apply reproduc-
ibly, especially in clinically staged patients.17 After 17 years, 
it is definitely time for a data-driven revision.
The robust data presented in the initial retrospective 
analysis of the International Association for the Study of 
Lung Cancer mesothelioma database in this issue of the 
Journal of Thoracic Oncology highlights key deficiencies of 
the current staging system and provides insights into how it 
could be revised.18 This effort, once again led by Dr. Rusch, 
evaluated information on 3101 patients from 15 centers in 
four continents. Though a far cry from the over 100,000 non–
small-cell lung cancer patients analyzed by the International 
Association for the Study of Lung Cancer when the lung 
cancer staging system was being similarly revamped,19,20 it is 
by far the largest series ever assembled on this less prevalent 
disease. It provides a wealth of data and is truly a seminal 
achievement.
In many ways, this data set confirms much of what we 
already suspected about the current staging system. For the 
medical oncologist, who is required to document the stage of 
a nonsurgical patient for clinical trial enrollment, determining 
the correct T stage often entails some frustrating guesswork. 
It is nearly impossible to clinically distinguish between T1a 
(parietal pleural involvement), T1b (minimal visceral pleural 
involvement), and T2 (involvement of all pleural surfaces, 
plus the diaphragm, fissures, or pulmonary parenchyma), nor 
is it possible to clinically ascertain those features required for 
a T3 designation, such as endothoracic fascia or nontransmu-
ral pericardial involvement. So it comes as no surprise that up 
to 80% of the patients clinically thought to have stage I or II 
disease were subsequently upstaged at surgery. The absence 
of statistically significant differences in outcomes for T1 and 
T2 disease suggests that other anatomic parameters need to be 
considered in early-stage disease.
Many of us assumed that an approach to lymph node 
staging that was borrowed from non–small-cell lung cancer 
would probably not be applicable to a disease whose pattern of 
lymphatic dissemination originates closer to the mediastinum 
than to the hilum. Indeed, these data show that although the 




The Essential Foundation of a Revised Staging System for  
Pleural Mesothelioma
Hedy Lee Kindler, MD
Section of Hematology/Oncology, University of Chicago
Disclosure: The author was a member of the Advisory Board of the 
International Association for the Study of Lung Cancer Mesothelioma 
Domain, and is currently a member of the Board of Directors of the 
International Mesothelioma Interest Group and the Immediate Past 
President the International Mesothelioma Interest Group. The author was 
not involved in the analysis of the database. 
Address for correspondence: Hedy Lee Kindler, MD, Associate Professor 
of Medicine, Director, Gastrointestinal Oncology and Mesothelioma 
Programs, Section of Hematology/Oncology, University of Chicago, 5841 
S. Maryland Avenue, MC 2115 Chicago, IL 60647. E-mail: hkindler@
medicine.bsd.uchicago.edu
Journal of Thoracic Oncology
7
11












1624 Copyright © 2012 by the International Association for the Study of Lung Cancer
 Journal of Thoracic Oncology  •  Volume 7, Number 11, November 2012
presence or absence of lymph node metastases is prognostic, 
the N1 or N2 status is not.
Histology has long been known to be a very strong 
predictor of outcome in mesothelioma. The remarkably wide 
differences in survival observed between pathologic subtypes 
(19 versus 8 months for epithelial and sarcomatoid patients, 
respectively) provide a useful benchmark, and suggest that 
this powerful prognostic factor should probably be incorpo-
rated into the next iteration of the staging system.
Another important purpose of a staging system is to cat-
egorize patients by prognosis. The current system does this to 
some degree, but it could do better. Differences in outcomes 
between stages are delineated best in those patients who have 
undergone surgery with curative intent; for the rest, especially 
those in the earlier stages, the differences are less clearly defined.
With the caveats of the selection bias inherent in a retro-
spective series (whereby fitter patients undergo more aggressive 
treatment and thus seem to achieve superior outcomes) these 
data suggest that patients who receive more than one treatment 
modality (that is, surgery plus chemotherapy or radiation) live 
longer than those who only have surgery (20 versus 11 months, 
respectively, p < 0.0001). This is not surprising in a disease in 
which a microscopic complete resection is not thought to be 
achievable. What is likely to evoke greater controversy, how-
ever, is that curative-intent surgery (either EPP or P/D) seems 
to improve survival compared with palliative surgical interven-
tions (18 versus 12 months, respectively, p < 0.0001). Though 
some partisans might question pooling EPP and P/D together 
as curative-intent surgery, this is entirely appropriate, since a 
meta-analysis of 663 patients from three American institutions 
previously demonstrated essentially no survival difference, 
stage by stage, between these two procedures.21 In the current 
series, only stage I patients derived a substantial survival benefit 
from an EPP (40 months, compared with 23 months for a P/D), 
a hypothesis-generating finding that deserves further study.
This retrospective project was, of course, limited by 
the available data that could be collected. For the next itera-
tion of the staging system, additional tumor, node, metastasis 
descriptors need to be identified and validated. This is the role 
of the ongoing international prospective staging project, once 
again ably led by Dr. Rusch. For T descriptors, pleural thick-
ness at predefined regions of the pleura will be assessed, to 
better account for the potential prognostic impact of tumor 
bulk and anatomic extent. For N stage, alternative definitions 
of N status will be explored, including the number of positive 
nodes, intra- versus extrapleural location, and involved lymph 
node zones. Key prognostic factors, especially the impact of 
epithelial histology, will be evaluated. The inclusion of non-
surgically managed patients in the prospective data set will 
clarify the prognostic differences in more advanced disease.
In sum, this is a great beginning; it confirms what we 
already thought we knew and suggests key areas for modifica-
tion in the future.
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